ANZICS CTG Endorsed Study


Perioperative dexmedetomidine in high risk cardiac surgery evaluation

Study Description

This is a multinational double blind randomised placebo controlled evaluation of peri-operative dexmedetomidine starting at induction of anaesthesia.

Population: Adults undergoing cardiac surgery with eGFR < 60 ml/min OR undergoing a combined or complex aortic surgery. Exclusion criteria include salvage surgery, eGFR < 15 ml/min, dialysis dependent, extracorporeal support.

Sample size: 2600 patients. Stratified at randomisation according to eGFR lower or higher than 60 ml/min.

Intervention: Dexmedetomidine 0.7 mcg/kg/hour starting at induction of anaesthesia. Continued at 0.35 mcg/kg/hr till 24 hours after surgery or as clinically desirable. Comparator: Placebo infusion.

Outcome: MAKE90 = death + dialysis + persistent AKI at day 90.

Management Committee

Yahya Shehabi (Chair), Michael Bailey, Rinaldo Bellomo, Lauren Bulfin, Z Endre, John Fraser, Belinda Howe, Shay McGuinness, Rachael Parke, David Scott, Julian Smith and Steve Webb.

Administering Institution

ANZIC Research Centre, Monash University


Monash University, ANZCA Clinical Trials Network

Sample Size

2600 patients

Project Status as of June 2019

Preparation work has commenced.




Yahya Shehabi (email)